IMCR (Immunocore Holdings) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMCR Immunocore Holdings PLC IMCR
81 GF Score
Price $31.89
GF Value $45.41
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Immunocore Holdings Short-term investments?

Short-term investments only applies to insurance companies.

IMCR
81GF Score
Immunocore Holdings PLC IMCR
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immunocore Holdings (IMCR) Overvalued in 2026?

Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued. The current stock price of $31.89 is trading 29.8% below its estimated GF Value™ of $45.41. GuruFocus considers Immunocore Holdings to be Possible Value Trap.

Key valuation signals for IMCR:

  • Short-term investments:
  • GF Value™: $45.41 vs. price of $31.89 (29.8% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunocore Holdings Business Description

Other Exchanges 6YG:Germany
Address 92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
81GF Score

Get the complete analysis for IMCR

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.89
Price
$45.41
GF Value